A Phase 3 interventional study of SPD489 Low-Dose and SPD489 High-Dose in Negative Symptoms of Schizophrenia, sponsored by Shire. Withdrawn. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2021-06-03.
Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Schizophrenia by Takeda — none open to participants now, none under way, none of them phase 3. Schizophrenia · Takeda.
Among the 11 studies in Schizophrenia by Takeda, this one is the 11th largest by enrollment, is one of 2 that started in 2012, is one of 4 in phase 3, and was the 2nd registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →None of the 11 studies in Schizophrenia by Takeda is open now. The open studies under Schizophrenia, anywhere →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 20 across the 11 interventional studies. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Schizophrenia by Takeda, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To assess the safety and efficacy of SPD489 low-dose and high-dose treatment groups to placebo when given as adjunctive therapy to antipsychotic medication in clinically stable adults with persistent predominant negative symptoms of schizophrenia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: SPD489 Low-Dose
Drug: SPD489 High-Dose
Drug: Placebo
SPD489 20, 30, or 40 mg capsules taken once-daily for up to 26 weeks
Also known as: Vyvanse, Lisdexamfetamine dimesylate, LDX
SPD489 50, 60, or 70 mg capsules taken once-daily for up to 26 weeks
Also known as: Vyvanse, Lisdexamfetamine dimesylate, LDX
Placebo capsule taken once-daily for up to 26 weeks
Negative Symptom Assessment (NSA-16) total score
Time frame: up to 26 weeks
Positive and Negative Syndrome Scale (PANSS)
Time frame: up to 26 weeks
No study locations are listed for this record.
Start is estimated for Jan 2012; primary completion for Feb 2014, 24 months later.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lisdexamfetamine